

## MAP17 - PDZK1

|                                 |   |
|---------------------------------|---|
| <b>CONTACT INFORMATION:</b>     | Monoclonal Antibodies Unit. Centro Nacional de Investigaciones Oncológicas  |
| <b>STATUS:</b>                  | Validated   |
| <b>TYPE:</b>                    | mouse monoclonal  |
| <b>CLONE NAME:</b>              | 165C  |
| <b>PROTEIN:</b>                 | PDZK1-interacting protein 1-Protein DD96  |
| <b>PROTEIN WEB:</b>             | <a href="https://www.uniprot.org/uniprot/Q13113#names_and_taxonomy">https://www.uniprot.org/uniprot/Q13113#names_and_taxonomy</a> |
| <b>ANTIGEN USED:</b>            | GST-MAP17   |
| <b>FUSION PARTNER:</b>          | NS1/Ag4-1 (NS1) cells   |
| <b>ISOTYPE:</b>                 | IgG1  |
| <b>SPECIES REACTIVITY:</b>      | Human   |
| <b>PREPARATION AND STORAGE:</b> | Aliquot and store at 4C. Do not freeze  |
| <b>COMMERCIALIZED BY:</b>       | Millipore   |

### DESCRIPTION

---

May play an important role in tumor biology.

### REFERENCES

---

MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. Perez M, Praena-Fernandez JM, Felipe-Abrio B, Lopez-Garcia MA, Lucena-Cacace A, Garcia A, Leonart M, Roncador G, Marin JJ, Carnero A. PLoS One. 2013;8 (2).

MAP17 and the double-edged sword of ROS. Carnero A. Biochim Biophys Acta. 2012 Aug;1826 (1):44-52.

p38 $\beta$  limits the contribution of MAP17 to cancer progression in breast tumors. Guijarro MV, Vergel M, Marin JJ, Muñoz-Galván S, Ferrer I, Ramon y Cajal S, Roncador G, Blanco-Aparicio C, Carnero A. Oncogene. 2012 Oct 11;31(41):4447-59.

MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation. Guijarro MV, Link W, Rosado A, Leal JF, Carnero A.


Carcinogenesis. 2007 Dec;28(12):2443-50.

MAP17 enhances the malignant behavior of tumor cells through ROS increase. Guijarro MV, Leal JF, Blanco-Aparicio C, Alonso S, Fominaya J, Lleonart M, Castellvi J, Ramon y Cajal S, Carnero A. Carcinogenesis. 2007 Oct;28(10):2096-104.

MAP17 overexpression is a common characteristic of carcinomas. Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, Lleonart M, Castellvi J, Ruiz L, Ramon Y Cajal S, Carnero A. Carcinogenesis. 2007 Aug;28(8):1646-52.


## APPLICATIONS

| IHC Techniques                    | Clone | Dilution | Antibody concentration | Antigen retrieval method | Visualization kit | Positive control | Negative control | Protein localization | Positivity in other species |
|-----------------------------------|-------|----------|------------------------|--------------------------|-------------------|------------------|------------------|----------------------|-----------------------------|
| <b>Frozen tissue and cytopins</b> |       |          |                        |                          |                   |                  |                  |                      |                             |
| Recommended                       | 165C  | Neat     | supernatant            |                          |                   |                  |                  |                      |                             |
| <b>Paraffin tissue</b>            |       |          |                        |                          |                   |                  |                  |                      |                             |
| Recommended                       | 165C  | 1:5      | supernatant            |                          |                   | Kidney           |                  |                      |                             |
| <b>Immunofluorescence</b>         |       |          |                        |                          |                   |                  |                  |                      |                             |




**165C is able to detect human MAP17 protein in immunocytochemistry**

To confirm that 165C mAb recognizes human MAP17 protein, immunocytochemistry on frozen cytospin preparations of GFP-tagged MAP17 expressed in HEK293T was performed. Cytospin preparation of GFP transfected cells was used as negative control.



165C mAb can be used to detect MAP17 protein in human paraffin tissues.

| WB Techniques              | Clone | Dilution | Antibody concentration | Positive control | Negative control | Expected MW | Observed Mw | Positivity in other species |
|----------------------------|-------|----------|------------------------|------------------|------------------|-------------|-------------|-----------------------------|
| <b>Western Blotting</b>    |       |          |                        |                  |                  |             |             |                             |
| Recommended                | 165C  | Neat     | supernatant            | Kidney           |                  | 12kDa       | 12kDa       |                             |
| <b>Immunoprecipitation</b> |       |          |                        |                  |                  |             |             |                             |



**165C mAb is able to detect human MAP17 protein by WB.**

LANES

Lane 1 Human kidney (100ug) (+)

Lane 2 GST-MAP17 recombinant protein (0,1ug) (+)

Lane 3 GST-MAP17 recombinant protein (0,2ug) (+)